Your browser doesn't support javascript.
loading
The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity.
Kowalski, Dariusz M; Zaborowska-Szmit, Magdalena; Szmit, Sebastian; Jaskiewicz, Piotr; Krzakowski, Maciej.
Affiliation
  • Kowalski DM; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Zaborowska-Szmit M; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Szmit S; Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Jaskiewicz P; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Krzakowski M; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Transl Lung Cancer Res ; 13(6): 1426-1431, 2024 Jun 30.
Article in En | MEDLINE | ID: mdl-38973950
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Document type: Article Affiliation country: Country of publication: